Antitumor Effects of Six Ricin A-Chain Immunotoxins of Potential Use in the Treatment of Hodgkin’S Disease

  • Andreas Engert
  • Philip Thorpe
Part of the NATO ASI Series book series (NSSA, volume 199)


The fate of patients with Hodgkin’s disease who relapse or fail to achieve complete remission with first line treatment is ominous. Second line combination chemotherapy can produce good remission rates although cures are uncommon (Hagemeister et al, 1987; Santoro et al, 1986). Of those patients achieving complete remissions, 15–20% will develop a second malignancy as a chemotherapy-related side effect (Valagussa et al, 1986). Therefore new non-mutagenic agents are needed for the treatment of this disease.


L540 Cell Growth Index LS40 Cell Interdigitating Reticulum Cell Imperial Cancer Research Fund 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bernhard, M.I., Foon, K.A., Oeltmann, T.N., Key, M.E., Hwang, K.M., Clarke, G.C., Christensen, W.L., Hoyer, L.C., Hanna, M.G., Jr. and Oldham, R.K., 1983, Guinea pig line 10 hepatocarcinoma model: characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin A-chain, Cancer Res. 43:4420.PubMedGoogle Scholar
  2. Blakey, D.C., Watson, G.J., Knowles, P.P. and Thorpe, P.E., 1987, Effect of chemical deglycosylation of ricin A-chain on the in vivo fate and cytotoxic activity of an immunotoxin ccmposed of ricin A-chain and anti-thy 1.1. antibody. Cancer Res., 47:947.PubMedGoogle Scholar
  3. Chittal, S.M., Caveriviere, P., Schwarting, R., Gerdes, J., Al Saati, T., Rigal-Huguet, F., Stein, H. and Delsol, G., 1988, Monoclonal antibodies in the diagnosis of Hodgkin’s disease. The search for a rational panel. Am. J.Surg.Path., 12:9.PubMedCrossRefGoogle Scholar
  4. Engert, A., Burrows, F., Jung, W., Tazzari, P.L., Stein, H., Pfreundschuh, M., Diehl, V. and Thorpe, P., 1990, Evaliiation of ricin A-chain- containing immunotoxins directed against CD30 as potential reagents for the treatment of Hodgkin’s disease. Cancer Res., in press.Google Scholar
  5. Fraker, P.J. and Speak, J.C., 1978, Protein and cell membrane iodination with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3,6 diphenylglycouril, Biochem. Biophys. Res. Comm., 80:849.PubMedCrossRefGoogle Scholar
  6. Fulton, R.J., Blakey, D.C., Knowles, P.P., Uhr, J.W., Thorpe, P.E. and Vitetta, E.S., 1986, Purification of ricin Al, A2 and B chains and characterization of their C5rtotoxicity, J.Biol.Chem., 261:5314.PubMedGoogle Scholar
  7. Hagemeister, F.B., Tannir, N., McLaughlin, P., Salvador, P., Riggs, S., Velasquez, W.S. and Cabanillas, F., 1987, MIME chemotherapy (Methyl- GAG, Ifosfamide, Methothrexate, Etoposide) as treatment for recurrent Hodgkin’s disease, Clin.Oncol., 5:556.Google Scholar
  8. Hsu, S-M., Ho, Y-S. and Hsu, P-L., 1987, Effect of monoclonal antibodies anti-2H9, anti-IRac, and anti-HeFi-1 on the surface antigens of Reed-Stemberg cells, J.Natl.Cancer Inst., 5:1091.Google Scholar
  9. Hwang, K.M., Foon, K.A., Cheung, P.H., Pearson, J.W. and Oldham, R.K., 1984, Selective antitumor effect on LIO Hepatocarcinoma cells of a potent immunoconjugate ccanposed of the A-chain of abrin and a monoclonal antibody to a hepatoma-associated antigen. Cancer Res., 44:4578.PubMedGoogle Scholar
  10. Knowles, P.P. and Thorpe, P.E., 1987, Purification of immunotoxins containing ricin A-chain and abrin A-chain using Blue Sepharose CL-6B, Anal.Biochem., 160:440.PubMedCrossRefGoogle Scholar
  11. Leonard, J.E., Johnson, D.E., Shawler, D.L. and Dillman, R.O., 1988, Inhibition of human T-cell tumor growth by TlOl-ricin A-chain in an athymic mouse model. Cancer Res., 48:4862.PubMedGoogle Scholar
  12. Pfreundschuh, M., Mommertz, E., Meissner, M., Feller, A.C., Hassa, R., Krueger, G.R.F. and Diehl, V., 1988, Hodgkin and Reed-Stemberg cell associated monoclonal antibodies HRS-1 and HSR-2 react with activated cells of lymphoid and monocytoid origin. Anticancer Res., 8:217.PubMedGoogle Scholar
  13. Santoro, A., Viviani, P., Valagussa, P., Bonfante, V. and Bonadonna, G., 1986, CCNU, Etoposide and Prednimustine (CEP) in refractory Hodgkin’s disease, Semin.Oncol., 13(Suppl. 1):23.PubMedGoogle Scholar
  14. Scatchard, G., 1949, The attraction of proteins for small molecules and ions, Ann.N.Y.Acad.Sci., 51:660.CrossRefGoogle Scholar
  15. Schaadt, M., Diehl, V., Stein, H., Fonatsch, C. and Kirchner, H.H., 1980, Two neoplastic cell lines with imique features derived from Hodgkin’s disease, Int.J.Cancer, 26:723.PubMedCrossRefGoogle Scholar
  16. Schwab, U., Stein, H., Gerdes, J., Lembke, H., Kirchner, H., Schaadt, M. and Diehl, V., 1982, Production of a monoclonal antibody specific for Hodgkin and Stemberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature, 299:65.PubMedCrossRefGoogle Scholar
  17. Schwarting, R., Gerdes, J. and Stein, H., 1987, Ber-H2: a new monoclonal antibody of the Ki-1 family for the detection of Hodgkin’s disease in formaldehyde-fixed tissue sections, to: “Leucocyte Typing III”, J.A. McMichael, ed., Oxford University Press, Oxford.Google Scholar
  18. Stein, H., Mason, D.Y., Gerdes, J., O’Connor, N., Wainscoat, J., Pallesen, G., Gatter, K., Falini, B., Delsol, G., Lembke, H., Schwarting, R. and Lennert, K., 1985, The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Stemberg-Reed cells and histiocytic malignancies are derived from activated lymphoid cells. Blood, 66:848.PubMedGoogle Scholar
  19. Thorpe, P.E., Detre, S.I., Foxwell, B.M.J., Brown, A.N.F., Skilleter, D.N, Wilson, G., Forrester, J.A. and Stirpe, F., 1985, Modification of the carbohydrate in ricin with me taper iodate-cyanoborohydride mixtures. Effect on toxicity and in vivo distribution, Eur. J.Biochem., 147:197.PubMedCrossRefGoogle Scholar
  20. Thorpe, P.E., Wallace, P.M., Knowles, P.P. Reif, M.G., Brown, A.N.F., Watson, G.J., Knyba, R.E., Wawrzamczak, E.J. and Blakey, D.C., 1987, New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo, Cancer Res., 47:5924.PubMedGoogle Scholar
  21. Thorpe, P.E., Wallace, P.M., Knowles, P.P., Reif, M.G., Brown, A.N.F., Watson, G.J., Blakey, D.C. and Newell, D.R., 1988, Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res., 48:6396.PubMedGoogle Scholar
  22. Valagussa, P., Santora, A., Fossati-Belloni, F., Banti, A. and Bonadonna, G., 1986, Second acute leukemia and other malignancies following treatment for Hodgkin’s disease, J.Clin.Oncol., 4:830.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Andreas Engert
    • 1
  • Philip Thorpe
    • 1
  1. 1.Drug Targeting LaboratoryImperial Cancer Research FundLincoln’s Inn Fields, LondonUK

Personalised recommendations